IP Library Granted Patent US 7,189,749
Granted Patent B2
US 7,189,749 · App. 10/662,135 · Granted Mar 13, 2007

Substituted phenoxyacetic acids

Assignee: The Institutes for Pharmaceutical Discovery LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,749
App. No.
10/662,135
Granted
Mar 13, 2007
Kind
B2
Abstract

Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.

Claims (41)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof wherein

A is a C 1 –C 4 alkylene group optionally substituted with C 1 –C 2 alkyl or mono- or disubstituted with halogen;

X is oxygen, sulfur or NR 6 , wherein each R 6 is hydrogen, cyano or an alkyl group of 1–6 carbon atoms which may be substituted with one or more halogens;

R 1 , R 2 , R 3 and R 4 are each independently

hydrogen, halogen, or nitro, or an alkyl group of 1–6 carbon atoms optionally substituted with one or more halogens;

OR 7 , SR 7 , S(O)R 7 , S(O) 2 R 7 , C(O)N(R 7 ) 2 , or N(R 7 ) 2 , wherein each R 7 is independently hydrogen, an alkyl group of 1–6 carbon atoms which may be substituted with one or more halogens or benzyl, where the phenyl portion is optionally substituted with up to three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 )alkylamino;

phenyl which is optionally substituted with up to three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 )alkylamino;

phenoxy where the phenyl portion is optionally substituted with up to three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 )alkylamino; or

R 5 is hydroxy, C 1 –C 6 alkoxy, or —O − M + where M + is a cation forming a pharmaceutically acceptable salt; and

Ar represents benzothiazolyl which is optionally substituted with up to five groups independently selected from halogen, nitro, hydroxy, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkylthio, trifluoromethyl, trifluoromethoxy, C 1 –C 6 alkylsulfinyl, and C 1 –C 6 alkylsulfonyl.

2. A compound according to claim 1 , wherein A is CH 2 ; R 5 is hydroxy; and each of R 1 –R 4 are independently hydrogen, halogen, C 1 –C 2 alkyl, phenoxy, benzyloxy, or C 1 –C 2 alkoxy.

3. A compound of the formula:

or a pharmaceutically acceptable salt thereof wherein

A is a C 1 – 4 alkylene group optionally substituted with C 1 –C 2 alkyl;

X is oxygen, sulfur or NR 6 , wherein each R 6 is hydrogen, cyano or an alkyl group of 1–6 carbon atoms which may be substituted with one or more halogens;

R 1 , R 2 , R 3 and R 4 are each independently

hydrogen, halogen, an alkyl group of 1–6 carbon atoms which may be substituted with one or more halogens, nitro, OR 7 , SR 7 , S(O)R 7 , S(O) 2 NR 7 C(O)N(R 7 ) 2 or N(R 7 ) 2 , wherein each R 7 is independently hydrogen, an alkyl group of 1–6 carbon atoms which may be substituted with one or more halogens or benzyl, where the phenyl portion is optionally substituted with upto three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 )alkylamino;

phenyl which is optionally substituted with up to three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 )alkylamino;

phenoxy where the phenyl portion is optionally substituted with up to three groups independently selected from halogen, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, amino, and mono- or di(C 1 –C 6 ) alkylamino; or

R 5 is hydroxy, C 1 –C 6 alkoxy, or —O − M + where M + is a cation forming a pharmaceutically acceptable salt; and

R 13 , R 14 , R 15 and R 16 are independently hydrogen, halogen, nitro, hydroxy, C 1 –C 6 alkyl, C 1 –C 6 alkoxy, C 1 –C 6 alkylthio, trifluoromethyl, trifluoromethoxy, C 1 –C 6 alkylsulfinyl, or C 1 –C 6 alkylsulfonyl.

4. A compound according to claim 3 , wherein R 13 , R 14 , R 15 and R 16 , in combination, represent (a) three hydrogens and one of bromo, cyano or nitro, (b) hydrogen atoms and one or two of fluoro, chloro, hydroxy, (C 1 –C 6 )alkyl, (C 1 –C 6 )alkoxy, or trifluoromethyl, (c) one hydrogen atom and two fluoro or two methyl with one hydroxy or one (C 1 –C 6 )alkoxy, (d) one hydrogen atom and two fluoro and one methyl, or (e) one hydrogen and three fluoro groups.

5. A compound according to claim 3 , wherein R 13 , R 14 , R 15 and R 16 independently represent hydrogen, fluorine, chlorine, nitro, or trifluoromethyl.

6. A compound according to claim 3 , wherein A is methylene or ethylene.

7. A compound according to claim 6 , wherein R 13 , R 14 , R 15 and R 16 , in combination, represent (a) three hydrogens and one nitro, (b) hydrogen(s) and one, two, or three of fluoro, (c) hydrogen(s) and one or two of chloro, or (d) three hydrogens and one trifluoromethyl group.

8. A compound according to claim 7 , wherein A is methylene, and R 5 is hydroxy or C 1 –C 6 alkoxy.

9. A compound according to claim 8 , wherein R 2 and R 3 are independently hydrogen, halogen, C 1 –C 6 alkyl, alkoxy, amino, or mono or di(C 1 –C 3 alkyl)amino.

10. A compound according to claim 9 , wherein R 13 , R 14 and R 16 are fluorines and R 15 is hydrogen.

11. A compound according to claim 3 , wherein R 1 and R 4 are hydrogen, methyl or ethyl; and R 2 and R 3 are independently hydrogen, bromo, chloro, fluoro, C 1 –C 2 alkyl, phenoxy, benzyloxy, C 1 – 2 alkoxy, amino, or mono or di(C 1 –C 3 alkyl)amino.

12. A compound according to claim 3 , wherein R 1 and R 4 are hydrogen, methyl or ethyl; and R 2 and R 3 are independently hydrogen, bromo, chloro, fluoro, C 1 –C 2 alkyl, phenoxy, benzyloxy, C 1 –C 2 alkoxy, amino, or mono or di(C 1 –C 3 alkyl)amino.

13. A compound according to claim 12 , wherein both R 1 and R 4 are hydrogen or C 1 –C 3 alkyl.

14. A compound according to claim 13 , wherein at least one of R 2 and R 3 is hydrogen, and both R 1 and R 4 are hydrogen.

15. A compound according to claim 1 , which is

{5-Fluoro-2[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)carbamoyl]-phenoxy}-acetic acid;

{5-Fluoro-2[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)carbamoyl]-phenoxy}-acetic acid ethyl ester;

{5-Fluoro-2-[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-thiocarbamoyl]-phenoxy}-acetic acid;

{5-Fluoro-2-[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-thiocarbamoyl]-phenoxy}-acetic acid ethyl ester;

{5-Fluoro-2-[(5-trifluoromethyl-benzothiazol-2-ylmethyl)-carbamoyl]-phenoxy}-acetic acid; or

{5-Chloro-2-[(5-trifluoromethyl-benzothiazol-2-ylmethyl)-carbamoyl]-phenoxy}-acetic acid.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 .

Assignments (2)
SECURITY RELEASE LETTER Recorded Sep 12, 2005
From: MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO., BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2005, BVIII LLC.
To: INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C.; INSTITUTE FOR DIABETES DISCOVERY, L.L.C.
Reel/Frame 016513/0792 →
SECURITY AGREEMENT Recorded Mar 3, 2005
From: INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC, THE; INSTITUTE FOR DIABETES DISCOVERY, LLC
To: MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC
Reel/Frame 016323/0360 →
Continuity (4)
Continuation 1019596400 · Jul 16, 2002
Division 0960381700 · Jun 23, 2000
Provisional Application 6014106800 · Jun 25, 1999
Related Publication 20050239849A1 · Oct 27, 2005